Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study
Journal
The Lancet Global Health
ISSN
2214-109X
Date Issued
2022
Author(s)
Alejandro Jara
Eduardo A Undurraga
José R Zubizarreta
Cecilia González
Alejandra Pizarro
Johanna Acevedo
Katherinne Leo
Fabio Paredes
Tomás Bralic
Verónica Vergara
Marcelo Mosso
Francisco Leon
Ignacio Parot
Paulina Leighton
Pamela Suárez
Juan Carlos Rios
Heriberto García-Escorza
Type
Resource Types::text::journal::journal article
URL Institutional Repository
Cite this document
Jara, A., Undurraga, E. A., Zubizarreta, J. R., González, C., Pizarro, A., Acevedo, J., Leo, K., Paredes, F., Bralic, T., Vergara, V., Mosso, M., Leon, F., Parot, I., Leighton, P., Suárez, P., Rios, J. C., García-Escorza, H., & Araos, R. (2022). Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: A large-scale prospective cohort study. The Lancet Global Health, 10(6), e798-e806. https://doi.org/10.1016/S2214-109X(22)00112-7
Subjects
bnt162 vaccine
;
chadox1 ncov-19
;
covid-19
;
covid-19 vaccines
;
humans
;
prospective studies
;
sars-cov-2
;
coronavac
;
tozinameran
;
vaxzevria
;
adult
;
aged
;
article
;
chile
;
cohort analysis
;
comparative effectiveness
;
controlled study
;
coronavirus disease 2019
;
demography
;
female
;
health care cost
;
health insurance
;
hospitalization
;
human
;
intensive care unit
;
major clinical study
;
male
;
mortality
;
observational study
;
outcome assessment
;
prospective study
;
vaccination
;
epidemiology
;
prevention and control
;
prospective study